Why the study?
Does a strategy of PCI with sirolimus-eluting balloon and provisional DES reduce target vessel failure compared to systematic DES in all-comers with de novo coronary lesions?
Does a strategy of PCI with sirolimus-eluting balloon and provisional DES reduce target vessel failure compared to systematic DES in all-comers with de novo coronary lesions?
Answers are grounded in this paper and cite their sources.
The SELUTION DeNovo trial will determine if a sirolimus-eluting balloon strategy with provisional stenting is non-inferior to systematic drug-eluting stenting in all-comers with de novo coronary lesions.
SELUTION DeNovo trial is an open-label, multi-center international randomized trial comparing a strategy of PCI with SEB and provisional DES to a strategy of PCI with systematic DES on TVF at one and five years. Non-inferiority will be tested at one and five years. If non-inferiority is met at five years, superiority will be tested.
No takes yet. Share an insight, caveat, or question.
Spaulding et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: